Studies of Small DNA Virus Encoded Oncogenes in Viral Carcinogenesis Using Laboratory Model Systems
1 other identifier
interventional
40
0 countries
N/A
Brief Summary
Cancer is a devastating disease, presenting an immense disease burden to affected individuals and their families as well as health care systems with 10.9 million new cases and 6.7 million deaths per year. Approximately 12% of human cancers worldwide are caused by oncoviruses infection with more than 80% of cases occurring in the developing world. Tumor viruses can be classified into two groups based on their genetic material;
- 1.DNA tumor viruses:
- 2.Small DNA tumor viruses (Papilloma viruses, Polyoma viruses and adenoviruses).
- 3.Complex DNA tumor viruses (Herpes viruses and Hepatitis B viruses).
- 4.RNA tumor viruses ( Hepatitis C viruses and human T-cell leukemia virus "HTLV").
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P25-P50 for not_applicable
Started Sep 2017
Shorter than P25 for not_applicable
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
June 13, 2017
CompletedFirst Posted
Study publicly available on registry
June 15, 2017
CompletedStudy Start
First participant enrolled
September 1, 2017
CompletedPrimary Completion
Last participant's last visit for primary outcome
February 28, 2018
CompletedStudy Completion
Last participant's last visit for all outcomes
February 28, 2018
CompletedJune 15, 2017
June 1, 2017
6 months
June 13, 2017
June 14, 2017
Conditions
Outcome Measures
Primary Outcomes (1)
carcinogenesis
developing cancer cervix
6 months
Study Arms (2)
cases
EXPERIMENTALHPV detection HPV Genotyping HPV Oncogenes and oncoproteins
control
ACTIVE COMPARATORHPV detection HPV Genotyping HPV Oncogenes and oncoproteins
Interventions
Eligibility Criteria
You may qualify if:
- Age: 18 - 65 years old.
- Women who are positive for HPV diagnosed by routine screening.
- Women willing to participate in the study and sign an informed consent
You may not qualify if:
- Age extremes (less than 18 years old or more than 65 years old).
- Immuno-comprised patients, patients under steroid therapy or chemotherapy, or patients with serious medical illness that could affect their immune system.
- Unknown medical history.
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- Heba Momen kamellead
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Design
- Study Type
- interventional
- Phase
- not applicable
- Allocation
- NON RANDOMIZED
- Masking
- SINGLE
- Who Masked
- CARE PROVIDER
- Purpose
- BASIC SCIENCE
- Intervention Model
- PARALLEL
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR INVESTIGATOR
- PI Title
- assistant lecturer
Study Record Dates
First Submitted
June 13, 2017
First Posted
June 15, 2017
Study Start
September 1, 2017
Primary Completion
February 28, 2018
Study Completion
February 28, 2018
Last Updated
June 15, 2017
Record last verified: 2017-06